COMMERCIALIZATION Regulatory · Validation · Reimbursement

From clearance to adoption.

Everything it takes to bring cancer technology to market — the FDA pathway builders, validation at the apex, and the investors who back it.

Toolbox

FDA pathway builders

Pick the route that fits your device and assemble the submission step by step. Not sure which applies? Start with BDD to qualify the technology as new.

● Technology pathway · ppsexempt.com

Validate at the apex.

A cleared device still needs the evidence the field trusts. Through PPS Exempt Consilium, technology is proven at the eleven PPS-exempt apex centers — then cascades through the NCCN network, NCI-designated centers, and the community hospitals that treat most patients.

FDA LEVER

Breakthrough designation

The entry credential — built in the BDD Builder above.

THE APEX

Apex validation

The eleven cost-reimbursed centers generate the comparative evidence CMS now requires.

THE MARKET

Coverage & payment

NTAP / RAPID pathways carry validated technology into adoption.

PPS Exempt Consilium — a standing council for cancer technology. Validated at the apex. Adopted by the field.
Pipeline

New technology for cancer

Emerging technology moving toward the clinic, split by track. Submit a candidate, or develop these into a live, curated pipeline.

Medical device

0

Hardware, imaging, surgical, and diagnostic technology on a device pathway (BDD · 510(k) · De Novo · PMA).

Submit a device technology

Pharma

0

Therapeutics and biologics — targeted agents, immunotherapies, ADCs, and cell therapies on a drug/biologic pathway.

Submit a therapeutic
Capital

For investors

Back the technology proven at the apex. Request access, review the pipeline, and get in touch.